Chinese innovative drugs developer Allist Pharmaceuticals has raised RMB1.18 billion ($170.75 million) in a new funding round led by healthcare-focused private equity firm Shiyu Capital, according to an announcement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
